Metagenomi, Inc. announced that it has received $175 million as its first tranche in a round of funding led by new investors PFM Health Sciences, LP, Farallon Capital Management, L.L.C., and a leading global investment firm on January 25, 2022. The transaction included participation from new investors Eventide Asset Management, LLC, Deep Track Capital, LP, Frazier Management, L.L.C., Pura Vida Investments, LLC, Irving Investors LLC, Millennium Management LLC, Citadel Multi-Strategy Equities Master Fund Ltd. a fund managed by Citadel Advisors LLC, Novo Holdings A/S, Bristol-Myers Squibb Company, Moderna, Inc. Marshall Wace LLP and returning investors RA Capital Management, L.P., Humboldt Fund and Leaps by Bayer. The company has raised $300,000,000 in funding till date.

As a part of the transaction, Santhosh Palani from PFM Health Sciences, LP has joined the company's board of directors.